Bio-techne's simple western™ technology utilized in recent fda approval of zevaskyn™ cell-based gene therapy

Minneapolis , july 14, 2025 /prnewswire/ -- bio-techne corporation (nasdaq: tech) today announced that its simple western™ technology played a key role in supporting the fda approval of zevaskyn™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (rdeb), developed by abeona therapeutics® (nasdaq: abeo). throughout clinical development, simple western enabled precise identification and quantification of collagen vii, a complex therapeutic target critical to zevaskyn's potency, supporting lot release testing for the viral vector and the cell therapy in a gmp setting.
ABEO Ratings Summary
ABEO Quant Ranking